Form 8-K - Current report:
SEC Accession No. 0001213900-25-054949
Filing Date
2025-06-17
Accepted
2025-06-17 07:03:05
Documents
14
Period of Report
2025-06-17
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K ea0245870-8k_aldeyra.htm   iXBRL 8-K 25852
2 ALDEYRA THERAPEUTICS, INC. PRESS RELEASE DATED JUNE 17, 2025 ea0245870ex99-1_aldeyra.htm EX-99.1 16307
6 GRAPHIC image_003.jpg GRAPHIC 3807
  Complete submission text file 0001213900-25-054949.txt   218991

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE aldx-20250617.xsd EX-101.SCH 3011
4 XBRL LABEL FILE aldx-20250617_lab.xml EX-101.LAB 34239
5 XBRL PRESENTATION FILE aldx-20250617_pre.xml EX-101.PRE 22356
16 EXTRACTED XBRL INSTANCE DOCUMENT ea0245870-8k_aldeyra_htm.xml XML 3690
Mailing Address 131 HARTWELL AVENUE SUITE 320 LEXINGTON MA 02421
Business Address 131 HARTWELL AVENUE SUITE 320 LEXINGTON MA 02421 781-761-4904
Aldeyra Therapeutics, Inc. (Filer) CIK: 0001341235 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36332 | Film No.: 251051805
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)